These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 602991)

  • 1. [Improvement with the combination of L-dopa and benserazide of postural dysregulations of the cerebral circulation: preliminary study].
    Boismare F; Boquet J; Lefrançois J; Le Poncin M
    Agressologie; 1977; 18(5):285-6. PubMed ID: 602991
    [No Abstract]   [Full Text] [Related]  

  • 2. [Disappearance of the disordered postural regulation of cerebral circulation by the addition of benserazide in parkinsonism treated with L-dopa].
    Boismare F; Samson M; Pouliquen A; Hacpille L
    Therapie; 1976; 31(5):615-22. PubMed ID: 1013953
    [No Abstract]   [Full Text] [Related]  

  • 3. Letter: Levodopa and dopadecarboxylase in treatment of postural hypotension.
    Boismare F; Boquet J
    Br Med J; 1975 Mar; 1(5957):573. PubMed ID: 1139159
    [No Abstract]   [Full Text] [Related]  

  • 4. Report on 45-month treatment of parkinsonism with L-dopa, alone and in association with a decarboxilase inhibitor (Ro 4-4602).
    Chouza C; Romero S; Gomensoro JB
    Acta Neurol Latinoam; 1974; 20(1-4):116-38. PubMed ID: 4619960
    [No Abstract]   [Full Text] [Related]  

  • 5. [Variation in the pharmacologic affects of decarboxylase inhibitor in variable doses in man].
    Castaigne P; Rondot P; Taberlet A; Baumann N
    Biomedicine; 1974 Dec; 21(12):486-90. PubMed ID: 4462871
    [No Abstract]   [Full Text] [Related]  

  • 6. [Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine].
    Mizuno Y; Yoshida M; Obayashi T; Ueki A
    Rinsho Shinkeigaku; 1976 Jul; 16(7):511-9. PubMed ID: 986921
    [No Abstract]   [Full Text] [Related]  

  • 7. [Development of studies on the treatment of parkinsonian syndromes with levodopa. II. Long-term effects of L-DOPA alone or in combination with a decarboxylase inhibitor].
    Rabadeau Dumas JL; Rondot P; Cardon P
    Therapie; 1977; 32(2):161-72. PubMed ID: 898124
    [No Abstract]   [Full Text] [Related]  

  • 8. ["Beginning and end of dose" dyskinesias caused by L-DOPA].
    Lhermitte F; Agid Y; Signoret JL; Studler JM
    Rev Neurol (Paris); 1977 May; 133(5):297-308. PubMed ID: 897439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Psychological changes in parkinsonian patients during L-DOPA, amantidine, and L-DOPA + IDC treatment (author's transl)].
    Puca FM; Megna GF; Masi G; Specchio LM
    Riv Patol Nerv Ment; 1974 Oct; 95(5):676-84. PubMed ID: 4470268
    [No Abstract]   [Full Text] [Related]  

  • 10. [Results of prolonged treatment of Parkinson's disease with the L-dopa-benserazide combination].
    Casacchia M; Barba C; Ruggieri S; Zamponi A; Agnoli A
    Riv Neurol; 1974; 44(5):303-30. PubMed ID: 4217465
    [No Abstract]   [Full Text] [Related]  

  • 11. [CB 154 in the treatment of Parkinson's disease. Results in combination with L-dopa and decarboxylase inhibitor].
    Meco G; Casacchia M; Zamponi A; Agnoli A
    Acta Neurol (Napoli); 1976; 31(4):479-48. PubMed ID: 1037427
    [No Abstract]   [Full Text] [Related]  

  • 12. [Decarboxylase inhibitors combined with L-dopa in the treatment of Parkinson's disease].
    Rondot P
    Rev Prat; 1974 Mar; 24(15):1211-2, 1215-6, 1219. PubMed ID: 4416964
    [No Abstract]   [Full Text] [Related]  

  • 13. Correlation of clinical symptoms, HVA and 5-HIAA in csf and plasma L-DOPA in Parkinsonian patients treated with L-DOPA and L-DOPA + RO 4-4602.
    Campanella G; Algeri S; Cerletti C; Dolfini E; Jori A; Rinaldi F
    Eur J Clin Pharmacol; 1977 Apr; 11(4):255-61. PubMed ID: 862646
    [No Abstract]   [Full Text] [Related]  

  • 14. L-dopa plus dopa-decarboxylase inhibitor. Sleep organization in Parkinson's syndrome before and after treatment.
    Bergonzi P; Chiurulla C; Gambi D; Mennuni G; Pinto F
    Acta Neurol Belg; 1975; 75(1):5-10. PubMed ID: 1202895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of hypoxia-induced disturbances by previous treatment with benserazide and L-dopa in rats.
    Boismare F; le Poncin M; Belliard JP; Hacpille L
    Experientia; 1975 Oct; 31(10):1190-1. PubMed ID: 1204736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Our experience in the treatment of Parkinson's disease with L-dopa plus RO 4-4602 combination].
    Campanella G; Pennetta R
    Acta Neurol (Napoli); 1974; 29(3):252-63. PubMed ID: 4417098
    [No Abstract]   [Full Text] [Related]  

  • 17. [5 years of experience in the treatment of parkinsonism with L-dopa and its combination with Ro4-4602].
    Romero S; Chouza C; Gomensoro JB
    Neurol Neurocir Psiquiatr; 1976; 17(4):239-54. PubMed ID: 1018727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L-dopa and benserazide in the treatment of acute hepatic encephalopathy in infancy.
    Sinniah D; Chan LL
    Singapore Med J; 1980 Aug; 21(4):658-60. PubMed ID: 7221579
    [No Abstract]   [Full Text] [Related]  

  • 19. Mortality among Parkinson patients treated with L-dopa combined with a decarboxylase inhibitor.
    Zumstein H; Siegfried J
    Eur Neurol; 1976; 14(5):321-8. PubMed ID: 949985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Letter: A severe case of postural hypotension. Paradoxical treatment by L-dopa combined with an inhibitor of extracerebral dopa-decarboxylase].
    Boismare F; Boquet J
    Nouv Presse Med; 1975 Feb; 4(8):589. PubMed ID: 1129119
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.